{
    "clinical_study": {
        "@rank": "46712", 
        "arm_group": [
            {
                "arm_group_label": "Orteronel, 300 mg twice daily", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Bicalutamide 50 mg per day", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this randomized phase II open label trial is to determine the anti-tumor\n      activity of TAK-700 (Orteronel) as compared to bicalutamide in terms of clinical\n      progression-free survival in prostate cancer patients who failed 1st line treatment with\n      LHRH (luteinizing hormone-releasing hormone) agonists or surgical castration."
        }, 
        "brief_title": "TAK-700 in Castration Resistant Prostate Cancer", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Histologically confirmed diagnosis of prostate adenocarcinoma\n\n          -  Metastatic disease in bone or other lesions documented by imaging. Abnormal\n             99mTc-bone scan imaging must be confirmed by Computed Tomography (CT) Scan or\n             Magnetic resonance Imaging (MRI)\n\n          -  Progressive disease following 1st line androgen deprivation therapy with LHRH\n             (luteinizing hormone-releasing hormone) Agonists or surgical castration.\n             Recommendations of Prostate Cancer Working Group 2 (PCWG2)\n\n          -  WHO (World health organization) performance status \u2264 2\n\n          -  Life expectancy > 12 weeks\n\n          -  Adequate bone marrow function (Absolute neutrophil count (ANC) 1500/\u03bcL; platelets\n             100,000/\u03bcL)\n\n          -  Castrate serum levels of testosterone (< 50 ng/dL)\n\n          -  Adequate renal function: calculated creatinine clearance > 40 mL/minute\n\n          -  Adequate hepatic function:\n\n               -  Bilirubin: total bilirubin 1.5 Upper limit of Normal (ULN)\n\n               -  Asparate aminotransferase (AST) and/or Alanine aminotransferase (ALT) \u2264 2.5 x\n                  ULN in the absence of liver metastases or \u2264 5 x ULN if liver metastases are\n                  present\n\n          -  Patients of reproductive potential should use adequate birth control measures, as\n             defined by the investigator, during the study treatment period and for at least 4\n             months following the last study treatment. A highly effective method of birth control\n             is defined as those that result in low failure rate (i.e. less than 1% per year) when\n             used consistently and correctly\n\n          -  Before patient registration/randomization, written informed consent must be given\n             according to ICH/GCP (International conference on Harmonization-Good Clinical\n             Practices), and national/local regulations\n\n        Exclusion criteria\n\n          -  Cardiac function:\n\n               -  Screening calculated ejection fraction (Multi Gated Acquisition Scan (MUGA)\n                  scan, or by echocardiogram) must be \u2265 50%\n\n               -  No history of myocardial infarction, unstable symptomatic ischemic heart\n                  disease, ongoing arrhythmias of Grade > 2 thromboembolic events (e.g., deep vein\n                  thrombosis, pulmonary embolism, or symptomatic cerebrovascular events), or any\n                  other cardiac condition (e.g., pericardial effusion restrictive cardiomyopathy)\n                  within 6 months prior to first dose of study drug\n\n               -  Chronic stable atrial fibrillation on stable anticoagulant therapy is allowed\n\n               -  Absence of New York Heart Association Class III or IV heart failure\n\n               -  Absence of Electrocardiogram (ECG) abnormalities of: Q-wave infarction, unless\n                  identified 6 or more months prior to screening and QTc interval > 470 msec\n\n               -  No uncontrolled hypertension despite appropriate medical therapy defined as\n                  blood pressure >160/90 mmHg at 2 separate measurements no more than 60 minutes\n                  apart during the Screening visit\n\n          -  Prior radiotherapy but only for lymph nodes is allowed\n\n          -  Prior or concomitant therapy:\n\n               -  No intake of narcotic analgesia for bone pain\n\n               -  No prior treatment with non-steroidal antiandrogens, within 6 months prior to\n                  randomization\n\n               -  No anticancer therapy or treatment with another investigational agent within the\n                  last 4 weeks prior to randomization\n\n               -  No prior therapy with TAK-700, ketoconazole, abiraterone, aminoglutethimide or\n                  MDV3100\n\n               -  Patients taking bisphosphonates or denosumab are eligible if they have received\n                  a stable dose for 4 weeks or more prior to randomization. (These treatments may\n                  then be continued on study)\n\n          -  No known hypersensitivity to compounds related to TAK-700 or to TAK-700 excipients\n             (refer to Investigator's brochure)\n\n          -  No known gastrointestinal (GI) disease or GI procedure that could interfere with the\n             GI absorption or tolerance of TAK-700, including difficulty swallowing tablets\n\n          -  No prior history of adrenal insufficiency\n\n          -  No prior history of malignancies other than prostate adenocarcinoma (except for basal\n             cell or squamous cell carcinoma of the skin), or the patient has been free of\n             malignancy for a period of 3 years prior to first dose of study drug\n\n          -  No known active chronic hepatitis B or C, life-threatening illness unrelated to\n             cancer, or any serious medical or psychiatric illness that could, in the\n             investigator's opinion, potentially interfere with participation in this study\n\n          -  No drug or alcohol abuse\n\n          -  Absence of any psychological, familial, sociological or geographical condition\n             potentially hampering compliance with the study protocol and follow-up schedule;\n             those conditions should be discussed with the patient before registration in the\n             trial"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01658527", 
            "org_study_id": "EORTC-1211", 
            "secondary_id": "2012-002122-67"
        }, 
        "intervention": [
            {
                "arm_group_label": "Orteronel, 300 mg twice daily", 
                "description": "Tak-700 will be administered until disease progression, diagnosis of a second malignancy, patient refusal to continue the treatment, excessive toxicity precluding further therapy according to protocol and /or according to the responsible physician.\nUpon progression, patient may stay on study medication until the initiation of a new therapy", 
                "intervention_name": "Orteronel", 
                "intervention_type": "Drug", 
                "other_name": "TAK 700"
            }, 
            {
                "arm_group_label": "Bicalutamide 50 mg per day", 
                "description": "Bicalutamide will be given at the standard daily dose of 50 mg PO (per os). Bicalutamide will be maintained until disease progression diagnosis of a second malignancy, patient refusal to continue the treatment, excessive toxicity precluding further therapy according to protocol and /or according to the responsible physician.", 
                "intervention_name": "Bicalutamide", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Bicalutamide"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "metastatic", 
            "prostate cancer"
        ], 
        "lastchanged_date": "January 23, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Yvoir", 
                    "country": "Belgium"
                }, 
                "name": "CHU Dinant Godinne - UCL Namur"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase II Randomized Comparative Trial of TAK-700 (Orteronel) Versus Bicalutamide in Metastatic Prostate Cancer Patients Failing 1st Line Treatment With LHRH Agonists or Surgical Castration.", 
        "overall_contact": {
            "email": "julie.hermans@eortc.be", 
            "last_name": "Julie Hermans, PhD", 
            "phone": "003227741673"
        }, 
        "overall_official": [
            {
                "affiliation": "San Camillo Forlanini Hospitals, Rome, Italy", 
                "last_name": "Cora Sternberg", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Cliniques Universitaires de St Luc, Brussels, Belgium", 
                "last_name": "Bertrand Tombal", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Belgium: Federal Agency for Medicinal Products and Health Products", 
                "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
                "United Kingdom: Research Ethics Committee"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint of the trial is clinical progression free survival. In this protocol, it is defined according to the recommendations of the \"Prostate-Cancer clinical trials Working Group 2\" and referred to as the \"PCWG2\" for the setting \"delay/prevent\" progression.", 
            "measure": "The primary endpoint of the trial is clinical progression free survival.", 
            "safety_issue": "No"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01658527"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "RECIST (Response Evaluation Criteria In Solid Tumors) response in patients presenting with measurable disease", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Time to PSA (Prostate specific antigen) progression and PSA change from baseline", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Safety according to Common Terminology Criteria for Adverse Events, version 4.03", 
                "safety_issue": "Yes"
            }, 
            {
                "measure": "Pain (when an SAE (Serious Adverse Event)) or pain requiring initiation of narcotic analgesia", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Skeletal related events, including requirement to initiate chemotherapy, radiotherapy, cord compression or requirement for surgery to the bone", 
                "safety_issue": "No"
            }
        ], 
        "source": "European Organisation for Research and Treatment of Cancer - EORTC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "European Organisation for Research and Treatment of Cancer - EORTC", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}